Peptide questions · VK2735
How long does VK2735 take to work?
Reviewed Evidence: ModeratePublished by PepVault
VK2735’s onset is days–2 weeks, its peak effect comes at 78 weeks (phase 3 endpoint, not yet read out), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Viking release, Mar-28-2023), phase 2 VENTURE RCT (Bays 2026, Obesity; NCT06068946), Viking updates Feb-11-2026 and Oct-28-2026, VANQUISH records on ClinicalTrials.gov. Investigational.
VK2735 week by week
The library places six of its research notes on VK2735 on the days they cover, from day 1 to day 546 and on: 4 on randomized trials and 2 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–21 (weeks 1–3) | Low start, first weeks | Randomized trial |
| Days 22–91 (weeks 4–13) | The first 13 weeks | Randomized trial |
| Days 22–546 (weeks 4–78) | The lowest phase 3 dose | Randomized trial |
| Days 43–546 (weeks 7–78) | The middle phase 3 dose | Randomized trial |
| Days 43–546 (weeks 7–78) | The top phase 3 dose | Clinical data |
| From day 150 on | Holding the loss on fewer shots | Clinical data |

Model. Individual results vary.
The VK2735 timeline’s milestones
The library’s timeline for VK2735 marks 5 points from week 1 to week 33, backed by moderate evidence overall.
- Week 1: Commonly reported: appetite dropping in the first days, with nausea most likely early
- Week 4: In the maintenance study, every dose had pulled clear of placebo by week 4
- Week 13: VENTURE's endpoint: about 9% (2.5 mg) to 15% (15 mg) average loss vs about 2% on placebo
- Week 21: Maintenance study: about 16% to 19% average loss after 21 weekly doses
- Week 33: Maintenance study: about 22% on a steady 17.5 mg weekly, still falling
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why VK2735 takes that long
VK2735’s half-life is about 9 days (216 hours), so one dose is about 96.9% cleared after 45 days.
On its schedule (Weekly) the doses overlap, and the level of VK2735 keeps climbing for about 36–45 days before it levels off, so the first 36–45 days run below the level the later weeks hold.
The notes on VK2735 follow the trials’ dose steps, 2.5mg, 7.5mg, 12.5mg and 17.5mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
VK2735 against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, VK2735 among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does VK2735 take to work?
VK2735’s onset is days–2 weeks, its peak effect comes at 78 weeks (phase 3 endpoint, not yet read out), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does VK2735 reach its peak effect?
By the library’s timeline, VK2735’s peak effect comes at 78 weeks (phase 3 endpoint, not yet read out), backed by moderate evidence.
How long is VK2735 usually run?
The library’s timeline gives VK2735’s typical duration as ongoing; its cycle note says: Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3.
What does the library say about the first days on VK2735?
Its first note on VK2735, for days 1–21 (weeks 1–3), is “Low start, first weeks”, resting on randomized trials.